Related Experiment Video

Updated: Jul 16, 2026

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

[Anti-beta 1 adrenoreceptor antibody is frequently elevated in patients with muscular dystrophy]

Tsuyoshi Matsumura1, Taku Yoshio, Keiji Yamamoto

  • 1Department of Neurology, National Hospital Organization Toneyama National Hospital.

Rinsho Shinkeigaku = Clinical Neurology
|February 28, 2007
PubMed

Insights

Anti-beta 1 adrenoreceptor antibody (ARAb) is present in progressive muscular dystrophy (PMD) patients, suggesting immune system involvement in cardiac impairment. ARAb elevation correlated with cardiac dysfunction in PMD and dilated cardiomyopathy (DCM).

Area of Science:

  • Immunology
  • Cardiology
  • Genetics

Context:

  • Dilated cardiomyopathy (DCM) is associated with various autoantibodies, including anti-beta 1 adrenoreceptor antibody (ARAb).
  • Progressive muscular dystrophy (PMD) patients experience significant cardiac dysfunction, with variable severity suggesting potential modifier factors.
  • The role of immune system in cardiac impairment in PMD remains unclear.

Purpose:

  • To measure anti-beta 1 adrenoreceptor antibody (ARAb) titers in patients with progressive muscular dystrophy (PMD) and dilated cardiomyopathy (DCM).
  • To investigate the potential role of immune function, specifically ARAb, in cardiac impairment associated with PMD.
  • To explore the correlation between ARAb levels and cardiac function parameters in PMD and DCM patients.

Summary:

  • Anti-beta 1 adrenoreceptor antibody (ARAb) titers were elevated in 30.1% of PMD patients and 72.7% of DCM patients.
  • In PMD patients with symptomatic cardiac failure, 75% had elevated ARAb.
  • ARAb levels showed weak correlations with fractional shortening, brain natriuretic peptide, noradrenalin, and premature ventricular contractions severity. Four PMD patients who developed cardiac failure showed increased ARAb.
  • Duchenne muscular dystrophy (DMD) patients on beta-blocker therapy showed decreased ARAb levels.

Impact:

  • This study highlights the presence of autoantibodies in PMD, similar to DCM, suggesting the immune system's role in cardiac dysfunction.
  • Findings emphasize the need for further investigation into immune system involvement to understand cardiac dysfunction mechanisms in PMD.
  • Results may inform refined cardiac treatment strategies for PMD patients, potentially including immunomodulatory approaches.

More Related Videos

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...